Has Jubin Ryu, MD received payments from drug or device companies?

Yes. Drug and device makers reported $181 in general payments to Jubin Ryu, MD across 8 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jubin Ryu, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jubin Ryu, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jubin Ryu, MD

Dermatology · Palo Alto, CANPI 1992021273

Payments from drug & device makers

$181in general payments, 2019–2025

Across 8 payments — averaging $22.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Pfizer$40
Arcutis Biotherapeutics, Inc.$36
UCB, Inc.$30
Novartis$28
AbbVie$26
Amgen$22

What the payments were for

Food & beverage$16692%
Education$158%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Pfizer	2	$40
Arcutis Biotherapeutics, Inc.	2	$36
UCB, Inc.	1	$30
Novartis	1	$28
AbbVie	1	$26
Amgen	1	$22

How this compares

$181 in reported general payments places this provider in the 15th percentile of 1,875 dermatology providers in California.

See all dermatology providers in California →

Medicare billing

Part B allowed, 2024

$536,344

Medicare patients

880

Services billed

7,888

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Dupixent PenDupilumab	27	$124,340
Fluorouracil	117	$8,184
Clobetasol Propionate	58	$4,572
Calcipotriene	14	$2,955
Ketoconazole	74	$1,660
Doxycycline Hyclate	49	$1,405
Tacrolimus	12	$1,386
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc	25	$1,319
Triamcinolone Acetonide	104	$1,160
Desonide	17	$1,089
Fluocinonide	34	$1,001
Metronidazole	13	$806
Clindamycin Phosphate	28	$803
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip	22	$690
Ciclopirox	14	$689

Paid to pharmacies, not to this prescriber.

Other dermatology in Palo Alto

Vivian LaquerIrvine$20.9M
Howard SofenLos Angeles$16.1M
Raja SivamaniSacramento$11.8M
Jennifer SoungSanta Ana$10.3M
Stacy SmithEncinitas$7.9M
Paul YamauchiSanta Monica$7.8M
Navid EzraThousand Oaks$7.8M
Paul WallaceBeverly Hills$7.1M
April ArmstrongLos Angeles$6.2M
David RayhanHuntington Beach$5.2M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →